Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Oncosec Medical (ONCS)

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,815
  • Shares Outstanding, K 39,185
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,250 K
  • 60-Month Beta 2.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.79
Trade ONCS with:

Options Overview

Details
  • Implied Volatility 159.80%
  • Historical Volatility 79.93%
  • IV Percentile 95%
  • IV Rank 55.55%
  • IV High 239.13% on 08/24/21
  • IV Low 60.66% on 06/14/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 636

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/21
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.84 +19.02%
on 08/19/21
2.42 -9.50%
on 09/01/21
+0.04 (+1.86%)
since 08/17/21
3-Month
1.84 +19.02%
on 08/19/21
4.25 -48.47%
on 07/07/21
-1.29 (-37.07%)
since 06/17/21
52-Week
1.84 +19.02%
on 08/19/21
8.16 -73.16%
on 02/01/21
-2.12 (-49.19%)
since 09/17/20

Most Recent Stories

More News
OncoSec Provides Leadership Update

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consisting of three board members, , Ph.D., ,...

ONCS : 2.19 (+9.50%)
OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, , and Senior Vice President, Chief Clinical...

ONCS : 2.19 (+9.50%)
Thinking about buying stock in Covanta, Vertex Energy, OncoSec Medical, Energous Corp, or Beam Therapeutics?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CVA, VTNR, ONCS, WATT, and BEAM.

ONCS : 2.19 (+9.50%)
VTNR : 6.09 (-1.77%)
WATT : 2.27 (+6.57%)
BEAM : 102.91 (+0.82%)
CVA : 20.11 (+0.10%)
Thinking about buying stock in OncoSec Medical, Dare Bioscience, Jaguar Health, Americas Gold and Silver, or Seelos Therapeutics?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCS, DARE, JAGX, USAS, and SEEL.

USAS : 0.9492 (-6.02%)
DARE : 1.7700 (+4.73%)
JAGX : 2.41 (+1.69%)
ONCS : 2.19 (+9.50%)
SEEL : 2.0000 (+1.52%)
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply Agreement ("Agreement") with...

MRK : 71.68 (-0.40%)
ONCS : 2.19 (+9.50%)
OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that has resigned and that , formerly Chief Operating Officer, has been appointed Interim...

ONCS : 2.19 (+9.50%)
Home Sales Featured in U.S., Retail Sales in Canada

Monday U.S. Featured Earnings OncoSec Medical Incorporated (NASDAQ:ONCS) (Q3) EPS projected ...

ONCS : 2.19 (+9.50%)
AVAV : 86.25 (-1.09%)
AFMD : 6.39 (+0.63%)
INFO : 121.73 (-1.66%)
KBH : 42.54 (+1.02%)
FUL : 60.72 (-2.58%)
PDCO : 30.98 (-1.37%)
WGO : 69.04 (-0.10%)
SCS : 13.64 (-0.29%)
PAYX : 108.78 (-0.54%)
KMX : 140.29 (+0.43%)
JKS : 48.08 (+2.43%)
MDP.TO : 3.26 (-2.10%)
OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of as Vice President of Product Engineering, effective .  Mr. Silverman,...

ONCS : 2.19 (+9.50%)
OncoSec to Present at the Raymond James Human Health Innovation Conference

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation...

ONCS : 2.19 (+9.50%)
OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of , Ph.D., a biotech industry veteran with over 20 years of experience,...

ONCS : 2.19 (+9.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

3rd Resistance Point 2.44
2nd Resistance Point 2.32
1st Resistance Point 2.25
Last Price 2.19
1st Support Level 2.06
2nd Support Level 1.94
3rd Support Level 1.87

See More

52-Week High 8.16
Fibonacci 61.8% 5.75
Fibonacci 50% 5.00
Fibonacci 38.2% 4.25
Last Price 2.19
52-Week Low 1.84

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar